A physician-scientist at the University of Oklahoma is part of an international effort seeking new options for patients with head and neck cancer who cannot receive the standard chemotherapy drug cisplatin.
The University of Oklahoma College of Medicine has named Jun Li, Ph.D., the founding chair of the newly created Department of Molecular Genetics and Genome Sciences, pending approval from the OU Board of Regents.